A Phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occl
Clinical Trial Grant
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 11, 2018
End Date
June 1, 2025
Administered By
Pediatrics, Hematology-Oncology
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
May 11, 2018
End Date
June 1, 2025